ArticleAmerican journal of cancer research2018
Immunotherapy strategy of EGFR mutant lung cancer.
Article in American journal of cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Association of CMTM6 expression with clinicopathological characteristics and prognostic implications in renal cell carcinoma.Therapeutic advances in medical oncology · 2026Article
- Article
- Homeobox D9 drives the malignant phenotypes and enhances the Programmed death ligand-1 expression in non-small cell lung cancer cells via binding to Angiopoietin-2 promoter.World journal of surgical oncology · 2023Article
- PELI1 and EGFR cooperate to promote breast cancer metastasis.Oncogenesis · 2023Article
- Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.The Journal of clinical investigation · 2023Article
- New research progress on 18F-FDG PET/CT radiomics for EGFR mutation prediction in lung adenocarcinoma: a review.Frontiers in oncology · 2023Review
- Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.Journal of cancer research and clinical oncology · 2022Article
- Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.eLife · 2022Article
- Network-based machine learning approach to predict immunotherapy response in cancer patients.Nature communications · 2022Article
- Coexpression of ΔNp63/p40 and TTF1 Within Most of the Same Individual Cells Identifies Life-Threatening NSCLC Featuring Squamous and Glandular Biphenotypic Differentiation: Clinicopathologic Correlations.JTO clinical and research reports · 2021Article
- Interpretable systems biomarkers predict response to immune-checkpoint inhibitors.Patterns (New York, N.Y.) · 2021Article
- Next-generation sequencing-based identification of EGFR and NOTCH2 complementary mutations in non-small cell lung cancer.Oncology letters · 2021Article
- Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma.Molecular therapy oncolytics · 2021Article
- Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis.Journal of thoracic disease · 2021Article
- Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma.Frontiers in oncology · 2021Article
- Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing.Translational oncology · 2021Article
- Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.Cancer medicine · 2021Review
- ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.Theranostics · 2021Article
- Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.Pathology oncology research : POR · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EGFR-mutant lung cancer is an important molecular subtype in Asia considering that almost 40%-50% of patients with lung adenocarcinoma in Asian carry the active EGFR mutaiton. People have greatly anticipated the efficacy of PD-1/PD-L1 monoclonal antibody in lung cancer treatment but anti-PD-1/PD-L1 treatment failed to positively affect these patients. The NCCN guidelines do not recommend immunotherapy to patients with NSCLC carrying EGFR mutation at present. However, the reason why EGFR-mutant lung cancer patients show poor response to anti-PD-1/PD-L1 treatment is still unknown. Immune suppression and tolerance are the main characteristics of tumor. The PD-1/PD-L1 co-inhibitory molecule is probably not the main escape route of this tumor type. The main characteristic of EGFR-mutant lung cancer is the activation of the EGFR signaling pathway. EGFR activation is likely responsible for the uninflamed tumor microenvironment of this type tumor and particiaptes in immunosuppression and immune escape. Accumulating evidence proved that activation of EGFR signaling pathway is essential to the generation of Treg and tolerogenic DCs. In this review, we summarize the efficacy of PD-1/PD-L1 monoclonal antibiodies in patients with EGFR-mutant lung cancer patients; provide evidence to analyze the potential reason why these patients cannot benefit from anti-PD-1/PD-L1 treatment, and explore the strategy that shoud be adopted in the future.
Indexed as
Identifiers
30416860PMC6220136W2901107610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.